Karyopharm Therapeutics Inc. (KPTI)
CIK 1503802 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 22.7M shares as of May 7, 2026 (10-Q). Share count fell from 17.05B to 18.3M between Oct 30, 2025 and Feb 5, 2026, a pattern consistent with a reverse split (roughly 1-for-930); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Two Thousand Twenty Five Warrants | 4.6M | $6.64 | — | — |
| Two Thousand Twenty Six Warrants | 4.4M | $10 | — | — |
| Pre Funded Warrants | 4.0M | $0.0001 | — | — |
| Maytwo Thousand Twenty Four Warrants | 3.1M | $16.5 | — | — |
| Two Thousand Twenty Four Warrants | 3.1M | $6.64 | — | — |
| Two Thousand Twenty Five Placement Warrants | 1.3M | $6.64 | — | — |
| Two Thousand Twenty Two Warrants | 635,703 | $95.37 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 14, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 18.0M underlying shares, as reported Mar 31, 2026 (10-Q).
Reported exercise price: $0.0001 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 40.7M = 22.7M O/S + 18.0M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Six Percentage Secured Convertible Senior Notes Due Two Thousand Twenty Nine | $111.0M | — | not tagged | — | — |
| New Two Thousand Twenty Nine Notes | $108.0M | $138.3M | $22.5 | — | ~4.8M sh |
| Two Thousand Twenty Nine Notes | $101.0M | — | $33.75 | — | ~3.0M sh |
| Two Thousand Twenty Eight Notes | $15.6M | $19.2M | $6.64 | — | ~2.4M sh |
If every note above converted at its tagged price: ~10.1M new shares on 22.7M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed May 14, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Registrations and offerings
Registered offering capacity on live registrations: $491.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 4 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full KPTI workspace